|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.87/-1.90
|
企业价值
599.14M
|
资产负债 |
每股账面净值
3.81
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/02 15:29 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powderinhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. |